114 related articles for article (PubMed ID: 26305064)
21. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.
Miranda LF; Gomes KB; Silveira JN; Pianetti GA; Byrro RM; Peles PR; Pereira FH; Santos TR; Assini AG; Ribeiro VV; Tito PA; Matoso RO; Lima TO; Moraes EN; Caramelli P
J Alzheimers Dis; 2015; 45(2):609-20. PubMed ID: 25589728
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of rivastigmine in Alzheimer's disease.
Nguyen K; Hoffman H; Chakkamparambil B; Grossberg GT
Neurodegener Dis Manag; 2021 Feb; 11(1):35-48. PubMed ID: 33198569
[TBL] [Abstract][Full Text] [Related]
24. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study.
Goekoop R; Rombouts SA; Jonker C; Hibbel A; Knol DL; Truyen L; Barkhof F; Scheltens P
Neuroimage; 2004 Dec; 23(4):1450-9. PubMed ID: 15589109
[TBL] [Abstract][Full Text] [Related]
25. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
26. Imaging treatment effects in Alzheimer's disease.
Venneri A
Magn Reson Imaging; 2007 Jul; 25(6):953-68. PubMed ID: 17446028
[TBL] [Abstract][Full Text] [Related]
27. Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment.
Bokde AL; Lopez-Bayo P; Meindl T; Pechler S; Born C; Faltraco F; Teipel SJ; Möller HJ; Hampel H
Brain; 2006 May; 129(Pt 5):1113-24. PubMed ID: 16520329
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.
Zamani M; Mohammadi M; Zamani H; Tavasoli A
Mol Neurobiol; 2016 Sep; 53(7):4521-8. PubMed ID: 26289409
[TBL] [Abstract][Full Text] [Related]
29. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
30. Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis.
Cader S; Palace J; Matthews PM
J Psychopharmacol; 2009 Aug; 23(6):686-96. PubMed ID: 18635705
[TBL] [Abstract][Full Text] [Related]
31. Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.
Ho BL; Kao YH; Chou MC; Yang YH
J Alzheimers Dis; 2016 Aug; 54(1):351-7. PubMed ID: 27567838
[TBL] [Abstract][Full Text] [Related]
32. Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?
Sobów T; Kłoszewska I; Flirski M; Liberski P
Neurol Neurochir Pol; 2009; 43(6):507-16. PubMed ID: 20054753
[TBL] [Abstract][Full Text] [Related]
33. Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease.
Solé-Padullés C; Bartrés-Faz D; Lladó A; Bosch B; Peña-Gómez C; Castellví M; Rami L; Bargalló N; Sánchez-Valle R; Molinuevo JL
J Clin Psychopharmacol; 2013 Apr; 33(2):199-205. PubMed ID: 23422370
[TBL] [Abstract][Full Text] [Related]
34. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients.
Bracco L; Bessi V; Padiglioni S; Marini S; Pepeu G
J Alzheimers Dis; 2014; 40(3):737-42. PubMed ID: 24577458
[TBL] [Abstract][Full Text] [Related]
35. Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment.
Penner J; Wells JL; Borrie MJ; Woolmore-Goodwin SM; Bartha R
Dement Geriatr Cogn Disord; 2015; 39(1-2):68-80. PubMed ID: 25358336
[TBL] [Abstract][Full Text] [Related]
36. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
37. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
38. Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.
Gallucci M; Spagnolo P; Aricò M; Grossi E
J Alzheimers Dis; 2016; 50(4):969-79. PubMed ID: 26836164
[TBL] [Abstract][Full Text] [Related]
39. Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity.
Sauer J; ffytche DH; Ballard C; Brown RG; Howard R
Brain; 2006 Jul; 129(Pt 7):1780-8. PubMed ID: 16670180
[TBL] [Abstract][Full Text] [Related]
40. Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study.
Teipel SJ; Bokde AL; Born C; Meindl T; Reiser M; Möller HJ; Hampel H
Brain; 2007 Jul; 130(Pt 7):1745-58. PubMed ID: 17566054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
